Seminars in Nephrology
Volume 24, Issue 4 , Pages 324-332 , July 2004

Nitric oxide and glomerulonephritis

  • Howard Trachtman

      Affiliations

    • Department of Pediatrics, Division of Nephrology, Schneider Children’s Hospital of Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY, USA
    • Corresponding Author InformationAddress reprint requests to Howard Trachtman, MD, Division of Nephrology, Schneider Children’s Hospital, 269-01 76th Ave, Room SCH365, New Hyde Park, NY 11040 USA

References 

  1. Ketteler M, Distler A. The role of nitric oxide in experimental glomerulonephritis. Kidney Blood Press Res. 1996;19:177–181
  2. Cattell V. Nitric oxide and glomerulonephritis. Kidney Int. 2002;61:816–821
  3. Cattell V. Nitric oxide and glomerulonephritis. Semin Nephrol. 1999;19:277–287
  4. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003;63:401–415
  5. Pfeilschifter J, Beck KF, Eberhardt W, et al.  Changing gears in the course of nephritis by shifting superoxide to nitric oxide-dominated chemistry. Kidney Int. 2002;61:809–815
  6. Li B, Yao J, Morioka T, et al.  Nitric oxide increases albumin permeability of isolated rat glomeruli via a phosphorylation-dependent mechanism. J Am Soc Nephrol. 2001;12:2616–2624
  7. Pfeilschifter J. Nitric oxide triggers the expression of proinflammatory and protective gene products in mesangial cells and the inflamed glomerulus. Nephrol Dial Transplant. 2002;17:347–348
  8. Lee SK, Kim CS, Yang WS, et al.  Exogenous nitric oxide inhibits tumor necrosis factor-alpha or interleukin-1-beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells. Role of IκB-alpha and cyclic GMP. Nephron. 2002;92:780–787
  9. Kashiwagi M, Masutani K, Shinozaki M, et al.  MCP-1 and RANTES are expressed in renal cortex of rats chronically treated with nitric oxide inhibitor (Involvement in macrophage and monocyte recruitment). Nephron. 2002;92:165–173
  10. Kashem A, Endoh M, Yano N, et al.  Expression of inducible-NOS in human glomerulonephritis (The possible source is infiltrating monocytes/macrophages). Kidney Int. 1996;50:392–399
  11. Waddington S, Cook TH, Reaveley D, et al.  L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates nephrotoxic nephritis. Kidney Int. 1996;49:1090–1096
  12. Waddington SN, Mosley K, Cattell V. Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis (Effects of selective inhibition in neutrophil-dependent glomerulonephritis). Clin Exp Immunol. 1998;113:258–264
  13. Gomez-Guerrero C, Lopez-Franco O, Suzuki Y, et al.  Nitric oxide production in renal cells by immune complexes (Role of kinases and nuclear factor-κB). Kidney Int. 2002;62:2022–2034
  14. Narita I, Border WA, Ketteler M, et al.  Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest. 1995;72:17–24
  15. Ishizuka I, Cunard R, Poucell-Hatton S, et al.  Agmatine inhibits cell proliferation and improves renal function in anti-Thy1 glomerulonephritis. J Am Soc Nephrol. 2000;11:2256–2264
  16. Peters H, Borders WA, Noble NA. L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int. 1999;55:2264–2273
  17. Goto S, Yamamoto T, Feng L, et al.  Expression and localization of inducible nitric oxide synthase in anti-Thy-1 glomerulonephritis. Am J Pathol. 1995;147:1133–1141
  18. Walpen S, Beck KF, Schaefer L, et al.  Nitric oxide induces MIP-2 transcription in a rat renal mesangial cells and in a rat model of glomerulonephritis. FASEB J. 2001;15:571–573
  19. Ketteler M, Westenfeld R, Gawlik A, et al.  Nitric oxide synthase isoform expression in acute versus chronic anti-Thy1 nephritis. Kidney Int. 2002;61:826–833
  20. Mosley K, Waddington SN, Ebrahim H, et al.  Inducible nitric oxide synthase induction in Thy1 glomerulonephritis is complement and reactive oxygen species dependent. Exp Nephrol. 1999;7:26–34
  21. Lopez-Franco O, Suzuki Y, Sanjuan G, et al.  Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune nephritis. Am J Pathol. 2002;161:1497–1505
  22. Lianos EA, Liu J. changes in inducible nitric oxide synthase expression in experimental glomerulonephritis. Proc Soc Exp Biol Med. 1997;215:405–411
  23. Bremmer V, Tojo A, Kimura K, et al.  Role of nitric oxide in rat nephrotoxic nephritis (Comparison between inducible and constitutive nitric oxide synthase). J Am Soc Nephrol. 1997;8:1712–1721
  24. Cook HT, Jansen A, Lewis S, et al.  Arginine metabolism in experimental glomerulonephritis (Interaction between nitric oxide synthase and arginase). Am J Physiol. 1994;267:F646–F653
  25. Waddington SN, Tam FWK, Cook TH, et al.  Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. Am J Physiol. 1998;274:F473–F480
  26. Waddington SN, Mosley K, Cook TH, et al.  Arginase AI is upregulated in acute immune complex-induced inflammation. Biochem Biophys Res Commun. 1998;247:84–87
  27. Waddington SN. Arginase in glomerulonephritis. Kidney Int. 2002;61:876–881
  28. Datta PK, Reddy RS, Lianos EA. Effects of all-trans retinoic acid (atRA) on inducible nitric oxide synthase (iNOS) activity and transforming growth factor beta-1 production in experimental anti-GBM antibody-mediated glomerulonephritis. Inflammation. 2001;25:351–359
  29. Ogawa D, Shikata K, Matsuda M, et al.  Protective effect of novel and selective inhibitor of inducible nitric oxide synthase on experimental crescentic glomerulonephritis in WKY rats. Nephrol Dial Transplant. 2002;17:2117–2121
  30. Waddington SN, Mosley K, Cattell V. Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis (Effects of selective inhibition in neutrophil-dependent glomerulonephritis). Clin Exp Immunol. 1999;118:309–314
  31. Lianos EA, Guglielmi K, Sharma M. Regulatory interactions between inducible nitric oxide synthase and eicosanoids in glomerular immune injury. Kidney Int. 1998;53:645–653
  32. Datta PK, Koukouritaki SB, Hopp KA, et al.  Heme-oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis. J Am Soc Nephrol. 1999;10:2540–2550
  33. Datta PK, Gross EJ, Lianos EA. Interactions between inducible nitric oxide synthase and heme oxygenase-1 in glomerulonephritis. Kidney Int. 2002;61:847–850
  34. Nihei T, Arai Km Miura Y, Yagasaki K. Arginine as an exacerbating factor for glomerulonephritis in rats fed a methionine-threonine-supplemented low casein diet. Biosci Biotechnol Biochem. 2001;65:1155–1162
  35. Cook HT, Sullivan R. Glomerular nitrite synthesis in in situ immune complex glomerulonephritis in the rat. Am J Pathol. 1991;139:1047–1052
  36. Weinberg JB. Nitric oxide as an inflammatory mediatorin autoimmune MRL-lpr/lpr mice. Environ Health Perspect. 1998;106:1131–1137
  37. Reilly CM, Oates JC, Cook JA, et al.  Inhibition of mesangial nitric oxide production in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000;164:1498–1504
  38. Keng T, Privalle CT, Gilkeson GS, et al.  Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol Med. 2000;6:779–792
  39. Reilly CM, Farrelly LW, Viti D, et al.  Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of nitric oxide synthase. Kidney Int. 2002;61:839–846
  40. Lui SL, Tsang R, Wong D, et al.  Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus. 2002;11: 4511–418
  41. Yu CC, Yang CW, Wu MS, et al.  Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med. 2001;138:69–77
  42. Yang CW, Yu CC, Ko YC, et al.  Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-β1) mRNA expression in NZB/W F1 mice. Clin Exp Immunol. 1998;113:258–264
  43. Peters H, Border WA, Ruckert M, et al.  L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int. 2003;63:1382–1392
  44. Van Goor H, Albrecht EW, Heeringa P, et al.  Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-12 nephritis. Nitric Oxide. 2001;5:525–533
  45. Westenfeld R, Gawlik A, de Heer E, et al.  Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy1 nephritis. Kidney Int. 2002;61:834–838
  46. Ferrario R, Takahishi K, Fogo A, et al.  Consequence of acute nitric oxide synthesis inhibition in experimental glomerulonephritis. J Am Soc Nephrol. 1994;4:1847–1854
  47. Heeringa P, van Goor H, Moshage H, et al.  Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int. 1998;53:382–393
  48. Heeringa H, Steenbergen E, van Goor H. A protective role for endothelial nitric oxide synthase in glomerulonephritis. Kidney Int. 2002;61:822–825
  49. Wagner L, Riggleman A, Erdely A, et al.  Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int. 2002;62:532–536
  50. Heeringa P, van Goor H, Itoh-Lindstrom Y, et al.  Lack of endothelial nitric oxide synthase aggravates murine accelerated murine anti-glomerular basement membrane glomerulonephritis. Am J Pathol. 2000;156:879–888
  51. Cattell V, Cook HT, Ebraihim H, et al.  Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase type 2. Kidney Int. 1998;53:932–936
  52. Uhlenius N, Tikkanen T, Miettinen A, et al.  Renoprotective effect of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. Nephron. 1999;81:221–229
  53. Uhlenius N, Tikkanen T, Tikkanen T, et al.  Chronic inhibition of nitric oxide synthase in Heymann nephritis. Nephron. 1996;74:144–149
  54. Walker LM, Shah SV, Mayeux PR. Lack of a role for inducible nitric oxide synthase in an experimental model of nephritic syndrome. Biochem Pharmacol. 2000;60:137–1453
  55. Furusu A, Miyazaki M, Abe K, et al.  Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int. 1998;53:1760–1768
  56. Romagnani P, Lazzeri E, Lasagni L, et al.  IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol. 2002;13:53–64
  57. Kakoki M, Matsumoto A, Nagata D, et al.  Analysis of nitric oxide in exhaled air of patients with chronic glomerulonephritis. Clin Nephrol. 1999;52:83–90
  58. Duan SB, Liu FY, Luo JA, et al.  Assessment of urinary endothelin-1 and nitric oxide levels and their relationship with clinical and pathologic types in primary glomerulonephritis. Yonsei Med J. 1999;40:425–429
  59. Ho CY, Wong CK, Li EK, et al.  Elevated plasma concentrations of nitric oxide, soluble thrombomodulin, and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. J Rheumatol. 2003;42:117–122
  60. Wong CK, Ho CY, Li EK, et al.  Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol. 2002;130:345–351
  61. Belmont HM, Levartovsky D, Goel A, et al.  Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:1810–1816
  62. Wang JS, Tseng HH, Shih DF, et al.  Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron. 1997;77:404–411
  63. Gilkeson G, Cannon C, Oates J, et al.  Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1998;26:318–324
  64. Oates JC, Christensen EF, Reilly CM, et al.  Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus (Correlation with disease activity). Proc Assoc Am Physicians. 1999;111:611–621
  65. Gonzalez-Crespo MR, Navarro JA, Arenas J, et al.  Prospective study of serum and urinary nitrite levels in patients with systemic lupus erythematosus. Br J Rheumatol. 1998;37:972–977
  66. Roccatello D, Mosso R, Ferro M, et al.  Urinary endothelin in glomerulonephritis patients with normal renal function. Clin Nephrol. 1994;41:323–330
  67. Roccatello D, Mengozzi G, Ferro M, et al.  Isosorbide 5-mononitrate administration increases nitric oxide blood levels and reduces proteinuria in IgA glomerulonephritis patients with abnormal urinary endothelin/cyclic GMP ratio. Clin Nephrol. 1995;44:163–169
  68. Amore A, Cirina P, Conti G, et al.  Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol. 2001;12:1862–1871
  69. Kovacs T, Barta J, Kocsis B, et al.  Nitric oxide in IgA nephropathy patients with or without hypertension. Exp Nephrol. 1995;3:369–372
  70. Trachtman H, Gauthier BG, Frank R, et al.  Increased urinary nitrite excretion in children with minimal change nephrotic syndrome. J Pediatr. 1996;128:173–176
  71. Soylemezoglu O, Ozkaya O, Erbas D, et al.  Nitric oxide in Henoch Shoenlein purpura. Scand J Rheumatol. 2002;31:271–274

PII: S0270-9295(04)00052-X

doi: 10.1016/j.semnephrol.2004.04.004

Seminars in Nephrology
Volume 24, Issue 4 , Pages 324-332 , July 2004

Article Tools